CytomX Therapeutics Inc. ($CTMX) experienced significant volatility following the release of data, with shares initially surging to $9.00 before dropping back below $5. The company's partnership with Amgen ($AMGN) for Phase 1a dose escalation updates was highlighted. Despite positive results in pancreatic cancer, concerns arose over minimal activity in other cancers, leading to a sharp decline in share price.